<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190849</url>
  </required_header>
  <id_info>
    <org_study_id>A094204</org_study_id>
    <secondary_id>174534</secondary_id>
    <nct_id>NCT04190849</nct_id>
  </id_info>
  <brief_title>European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)</brief_title>
  <acronym>EU-PNAFLD</acronym>
  <official_title>The European Paediatric Non-alcoholic Fatty Liver Disease Registry (EU-PNAFLD): a Prospective, Longitudinal Follow-up of Children With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The European Association for the Study of the Liver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Liver Disease Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European
      centres involved in the care of children with NAFLD, and will include Hepatologists,
      Endocrinologists, and Scientists, supported by relevant international specialists. This
      collaboration will build on existing infrastructure (local databases and bio-repositories)
      and will align with the adult European NAFLD Registry (&quot;EPoS&quot;, Elucidating Pathways of
      Steatohepatitis study) to allow long-term follow-up supported by translational studies.
      Through an international, well-characterised large-scale cohort, we hope to: facilitate
      multi-centre clinical trials; extend our understanding of the key disease mechanisms of
      NAFLD; and establish the natural history of paediatric NAFLD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2017</start_date>
  <completion_date type="Anticipated">November 2047</completion_date>
  <primary_completion_date type="Anticipated">November 2047</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Years</target_duration>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30-year follow-up</time_frame>
    <description>All-cause survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular morbidity</measure>
    <time_frame>30-year follow-up</time_frame>
    <description>CAD, CVA, PAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver morbidity</measure>
    <time_frame>30-year follow-up</time_frame>
    <description>Decompensated liver disease, transplantation, HCC development</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic progression of liver disease</measure>
    <time_frame>30-year follow-up</time_frame>
    <description>Presence of advanced fibrosis (on biopsy or non-invasive imaging)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Non-alcoholic Fatty Liver</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Non-alcoholic fatty liver disease patients</arm_group_label>
    <description>Children (&lt;18 years) with a diagnosis of NAFLD with radiological demonstration of increased liver fat and exclusion of other causes.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA blood for DNA extraction from patient (+/- both parents) (Fasting) serum for metabolite
      profiling
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children with NAFLD who have been diagnosed either invasively (i.e. using liver biopsy) or
        using some form of imaging (USS, MRI, CT, MRS) plus exclusion of secondary causes using an
        appropriate panel of bloods. This aims to facilitate recruitment from a representative
        population of children, not just those from specialist centres who have undergone biopsy.

        'Secondary NAFLD' (i.e. drug-induced, post-transplant) are not eligible. Children with
        insulin resistance syndromes are not specifically excluded however this is not the primary
        focus of EU-PNAFLD and other condition-specific registries are in existence.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis made under 18 years of age.

          -  Diagnosis of NAFLD spectrum disease (simple steatosis (NAFL), steatosis with abnormal
             transaminases, NASH ± fibrosis or cirrhosis)

          -  Diagnosis established by:

               -  Radiological evidence of hepatic steatosis (e.g. increased hepatic echogenicity
                  on ultrasound), with

               -  Exclusion of secondary causes (negative serological liver screen for HBV/HCV,
                  caeruloplasmin &gt;0.20g/L, no history of excess alcohol consumption, no evidence of
                  iron overload, and no clinically significant alpha-1 antitrypsin (A1AT) phenotype
                  (i.e. SZ, ZZ, SS), with or without

               -  Histology (&gt;5% steatosis and histology consistent with paediatric NAFLD)

        Exclusion Criteria:

          -  Secondary fatty liver disease (e.g. glycogen storage diseases, Wilson disease, viral
             hepatitis, drug-related, autoimmune hepatitis, type 1 diabetes mellitus)

          -  Post-transplant fatty liver

          -  &gt;20g/day ethanol intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B Savage</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jake P Mann, MRCPCH</last_name>
    <phone>0044124644</phone>
    <email>jm2032@cam.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jake P Mann</last_name>
      <phone>00447804124644</phone>
      <email>jm2032@cam.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Indra van Mourik</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Mann JP, Vreugdenhil A, Socha P, Jańczyk W, Baumann U, Rajwal S, Casswall T, Marcus C, van Mourik I, O'Rahilly S, Savage DB, Noble-Jamieson G, Lacaille F, Dabbas M, Dubern B, Kelly DA, Nobili V, Anstee QM. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemp Clin Trials. 2018 Dec;75:67-71. doi: 10.1016/j.cct.2018.11.003. Epub 2018 Nov 5.</citation>
    <PMID>30408605</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Jake Mann</investigator_full_name>
    <investigator_title>Wellcome Trust Clinical Fellow</investigator_title>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Liver disease</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared with researchers outside of the Registry</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT04190849/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

